| Id: | acc4904 |
| Group: | 1sens |
| Protein: | beta-catenin |
| Gene Symbol: | Ctnnb1 |
| Protein Id: | Q9WU82 |
| Protein Name: | CTNB1_RAT |
| PTM: | phosphorylation |
| Site: | Ser37 |
| Site Sequence: | QSYLDSGIHSGATTTAPSLSG |
| Disease Category: | Nervous system diseases |
| Disease: | Psychiatric Disorders |
| Disease Subtype: | |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | Lithium |
| Drug Info: | Lithium is a chemical element and a mood - stabilizing medication. It is commonly used in the treatment of bipolar disorder to help control mood swings. |
| Effect: | modulate |
| Effect Info: | "Lithium reduces the phosphorylation of beta-catenin at the Ser33/Ser37/Thr41 sites, thereby decreasing its degradation rate, indirectly enhancing the activity of the Wnt pathway, and potentially participating in the regulation of GluN2A expression." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 29449801 |
| Sentence Index: | 29449801_3 |
| Sentence: | "Lithium, a clinically relevant drug commonly prescribed as a mood stabilizer for psychiatric disorders, significantly increased levels of phosphorylated GSK3beta serine 9, an inhibitory phosphorylation site, and decreased beta-catenin ser33/37/thr41 phosphorylation in vitro, indicating GSK3beta inhibition and reduced beta-catenin degradation." |
Sequence & Structure:
MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDTSQVLYEWEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSKKEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGPHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLVRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFVQLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFRMSEDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEALGYRQDDPSYRSFHSGGYGQDALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDL
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 37 | N | Colorectal cancer | Phosphorylation | 11181454 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
